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Abstract
Background: There has been increased demand for greater public accountability and transparency of private
sector-led global health partnership programs. This study critically reviews and pilot tests the World Health
Organization (WHO) medicine program checklist as a framework for public reporting and assessing of programs.
Methods: We reviewed each question on the WHO checklist for clarity and usability. Next, we pilot tested the
subset of checklist questions focused on program assessment. We extracted and analyzed publicly available
information on one randomly selected program from each of the 20 largest research-based biopharmaceutical
companies. For each program, we assessed whether publicly available information allowed for an assessment of
each relevant question in the checklist.
Results: Checklist questions fit in four main categories: [1] national health and development plans, needs, capacity,
laws and policies; [2] financial, performance, and public accountability; [3] risk management and mitigation
strategies; and [4] long-term sustainability. Nearly all (21 of 22) questions in the checklist require information best
provided by companies; one question requires information best provided by governments.
Programs frequently reported on the public health needs of their programs (100%), program objectives and
activities (100%) and the actual or expected program outputs (95%). There was less information on program
alignment with country plans and capacity (50%), detailed program monitoring and evaluation plan (20%), risks
mitigation strategies (5%), program needs assessment (5%), and additional resources required from or contributed
by government (0%).
Conclusion: The WHO checklist of key considerations for evaluating proposals for access to medicine programs
could be a useful framework for public reporting of program information as most of checklist questions ask for data
that should be available to those leading the program. Further revisions of the WHO checklist will help refine it to
improve clarity and content validity.
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Background
The number and scope of public health programs imple-
mented by biopharmaceutical companies to promote ac-
cess to care and medicines for people in low- and
middle-income countries has increased in recent years
[1]. This increase has triggered wider discussions on the
gaps in program performance monitoring and evaluation
[2, 3], public policies on the roles of the private sector
[4], and public accountability including the absence of
an assessment tool to guide governments in their review
of program development, implementation and regulation
[5]. While private sector companies are traditionally ac-
countable to shareholders and investors, and public sec-
tor organizations are accountable to the political
structures, there has been lack of public accountability
and transparency of global health public-private partner-
ship programs [6, 7]. The World Health Organization
has defined accountability within health systems as “a re-
lationship between a duty holder and a person or
organization to whom a duty is owed. It describes the
capacity to demand that a person or organization give
reasons to justify their behavior and the capacity to im-
pose a sanction if they fail to give reasons, or if their per-
formance is poor.” [8] Transparency is often regarded as
a prerequisite for accountability [9].
Many programs implemented by biopharmaceutical
companies seem to appreciate the importance of public
transparency and accountability by hosting a website
and publishing annual reports; however, these usually
contain little information on program governance, needs
assessment and alignment with country plans and cap-
acity, detailed program plan, program impact and sus-
tainability plans [7]. When programs are open and
forthcoming with information on all aspects of the pro-
gram, this allows program assessment by stakeholders
which helps to build public trust in the program [10].
In 2017, the World Health Organization (WHO) pub-
lished a checklist of key considerations that governments
should consider when evaluating proposals for access to
medicine programs from medicines and medical device
companies (hereafter referred to as the "WHO check-
list") [5]. The motivation for such a checklist was the
need for guidance of how to evaluate whether a program
aligns with national health and development plans,
needs, capacity, laws and policies; has mechanisms to
ensure financial, performance, and public accountability;
has risk management and mitigation strategies and has
transitioning plans for long-term sustainability.
Although the WHO checklist was developed to provide
a uniform framework through which programs can pro-
vide information to governments, it could also serve as a
useful framework for public reporting of program infor-
mation in the absence of any other reporting framework.
It is important that the public is not only informed of the
programs successes and lessons learned as is currently the
case but has access to the evidence and assumptions used
to inform program planning such as needs assessment
documents, detailed program plan, monitoring and evalu-
ation plan, sustainability plans and potential conflict of
interest [10].
The objective of this study is to test the feasibility of
using the WHO checklist to assess key considerations
for evaluating proposals for access to medicine programs
as a framework for reporting program information. The
WHO checklist was designed to assess information sub-
mitted to government by companies and from our per-
spective all such program information should be in the
public sphere to ensure accountability and transparency
[11]. Based on this perspective, we reviewed publicly
available program information and made suggestions on
which program information responds to specific ques-
tions in the checklist and how the checklist could be
modified to serve as a framework for public program
reporting.
Methods
For the purpose of this study we defined access pro-
grams led by medicines and medical device companies
as those that are designed and co-financed by pharma-
ceutical companies and that they take responsibility and
credit for them (Rockers et al., 2018). Depending on the
industry-led program it could be implemented in collab-
oration with the government, other pharmaceutical com-
panies or NGOs. The program can be philanthropic or
has shared business and social goals.
We used a two-stage process in conducting this study.
In the first stage, we reviewed each question on the
WHO checklist for clarity and took note of double- or
multi-barreled questions (questions that had two or
more concepts in a single question). We also critically
reviewed the checklist to determine which questions re-
quire information best provided by companies versus
government when using the checklist as a framework for
public reporting of program information. We then de-
scribed each question on the checklist and provided ex-
amples of program information that may or may not be
good responses to each question on the checklist.
In the second stage, we extracted and analyzed pub-
licly available information of 20 biopharmaceutical in-
dustry led programs, with one program randomly
selected from each of the 20 largest research-based
pharmaceutical companies [12]. Our program sample
frame was each company’s list of global health partner-
ship programs in the International Federation of
Pharmaceutical Manufacturers and Associations
(IFPMA) World Health Partnerships Directory [13],
which to our knowledge has the most comprehensive
listing of pharmaceutical industry-led health programs.
Umeh et al. Journal of Pharmaceutical Policy and Practice            (2020) 13:5 Page 2 of 9
For the two companies, Gilead and Novo Nordisk, two
recent IFPMA members with no single company pro-
grams listed on the IFPMA directory as at the time of
our study, we randomly selected an ongoing program
from the company’s 2017 annual report (Gilead) and
company’s website (Novo Nordisk).
For the programs selected, two researchers independ-
ently searched online for program information and
reviewed program webpages, press releases, reports, and
peer reviewed articles. They also reviewed program in-
formation reported in the IFPMA Health Partnerships
Directory [13], Access Observatory [11] and Access Ac-
celerated Open Platform [14]. The Access Accelerated
Open Platform is a directory of Access Accelerated ini-
tiative programs, comprising of about 90 programs as of
December 2018 [14]. Access Accelerated is a partnership
of more than 20 global research and development-based
biopharmaceutical companies, working with partners in-
cluding the World Bank and the City Cancer Challenge
that seeks to reduce barriers to prevention, treatment
and care for patients with non-communicable diseases
in low- and middle-income countries.
Access Observatory is a public reporting platform with
the aim to improve access to disease prevention and
treatment services in low- and middle-income countries,
including those designed and implemented by public
and non-profit organizations. The Access Observatory
was created in 2017 to report and evaluate the Access
Accelerated programs [11].
For each program, the researchers independently noted
which of the program’s publicly available information re-
sponds to the questions on the WHO checklist. We con-
sidered programs that provided information on any of the
constructs in the double- or multi-barreled questions on
the WHO checklist, as having responded to that question.
Furthermore, we interpreted the question “Due diligence
on industry partner has been conducted” in Section 3 on
Strong Risk Management and Mitigation Strategies to
mean that companies have provided information on how
they assessed and selected their funding or implementing
partners. In our analysis, we combined the following two
questions in the WHO checklist, “The initiative can be
implemented under existing legislation and it adheres to
national regulations, procurement procedures, treatment
guidelines, and standards of care, quality and safety re-
quirements, remuneration scales and hiring practices” and
“The program is suitable for the existing infrastructure,
capacity, environment and local context”. Only if both
statements applied, did we check this combined item.
The researchers met to reach a consensus if there was
any disparity in the information they independently ex-
tracted. Thereafter, we calculated the proportion of pro-
grams with publicly available information on each of the
questions on the checklist.
Results
The WHO checklist has four domains and 23 questions
of key considerations to be taken into account by com-
panies when providing information on access to medi-
cine programs. Based on our analysis, information on 22
out of 23 questions could easily be provided by company
programs when using the checklist as a framework for
public reporting of program information. Governments
are in a better position to provide information on one of
the questions “There is sufficient support for the pro-
gram amongst political parties, unions, and civil society
organizations”. Two of the remaining 22 questions were
combined into one, leaving 21 in the final checklist. Six
of the questions (27%) contained two or more related
constructs in one question (Table 1).
Pilot testing the checklist using information from 20
programs showed that programs were more likely to
provide information on mechanisms to ensure financial,
performance, and public accountability (on average, 11
programs answered each of the eight questions in this
domain; 55%) (Table 2). This is followed by information
on how the programs align with the countries’ national
health and development plans, needs, capacity, laws and
policies (on average, eight programs answered each of
the seven questions in this domain; 40%) and transition-
ing plans for long-term sustainability (on average, six
programs answered each of the three questions in this
domain; 30%). Programs were least likely to provide in-
formation on risk management and mitigation strategies
(on average, one program answered each of the three
questions in this domain; 4%).
For the national health and development plans, needs,
capacity, laws and policies domain, programs clearly
stated their program objectives (n = 20/20; 100%), de-
scribed how their programs serve a public health need
(n = 20/20; 100%) and how their programs align with
health strategic plans and general development agenda
(n = 10/20; 50%). Only a few programs reported on how
their programs are suitable for existing infrastructure,
capacity, environment and local context (n = 4/20; 20%).
One program (a HIV screening and linkage to care pro-
gram) reported on how needs assessment was used to
inform program design. None of the programs provided
information on additional government resources re-
quired for their programs and none provided informa-
tion on how and/or why their programs divert or do not
divert resources away from other public health priorities.
For the financial, performance, and public accountabil-
ity domain, programs provided information on how the
programs will be implemented (n = 19/20; 95%), pro-
gram performance targets or outputs (n = 19/20; 95%),
parties responsible for overseeing and monitoring the
programs (n = 10/20; 50%) and the roles and responsibil-
ities of all identified stakeholders (n = 7/20; 35%). There
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Table 1 Description of program information that would fulfil the requirements of the corresponding checklist question
WHO checklist Description of program information from companies that align with the
checklist
Alignment with countries’ national health and development plans, needs, capacity, laws and policies
1 The program serves a public health need. A description of the health problem the program is trying to solve.
2 The policy objective is clear. Program objectives are clearly stated.
3 The program aligns with health strategic plans and the general
development agenda.a
A description of how the program aligns with the country’s health
strategic plan and/or development agenda. For multi-country programs,
a description of how the program aligns with the Sustainable Develop-
ment Goals or World Health Organization health goals might meet this
requirement.
4 The program is suitable for the existing infrastructure, capacity,
environment and local context.a b
A description of the design or implementation of programs in
accordance with country laws, policies and practices might meet this
requirement, e.g. treating patients using national treatment guidelines.
Just mentioning that the government and local stakeholders made
inputs to the program design might not meet this requirement.
5 Additional government resources (infrastructure, human resources or
funding) that are required have been identified and are available.a
A description of additional resources that are required from government
e.g. human resources and infrastructure.
6 The program does not divert resources away from other public health
priorities.
Information on how the additional resources that might be required
from government will not adversely affect other public health priorities.
7 The program has been compared to other approaches/programs/
programmes and has been found to be the most suitable.a
A formal needs assessment should provide information on the suitability
of the program.
Strong mechanisms to ensure financial, performance, and public accountability
1 Roles and responsibilities for all stakeholders involved are clear. A description of the roles and responsibilities of all named stakeholders
meets this requirement.
2 The mechanisms for how the program will be carried out are clear. A description of program activities might meet this requirement.
However, a more detailed work plan showing the program activities,
and the responsible party and timeline for each activity will be ideal.
3 Those responsible for overseeing and monitoring the program have
been identified.
A mention of the party responsible for monitoring or evaluating the
program might meet this requirement.
4 The process for monitoring and evaluation has been established. A description of the process for monitoring and evaluation of the
program. This may include a description of the performance indicators
and data collection and processing strategies.
5 Allocation, disbursement and utilization of financial resources have
been defined.a
The program should provide information on the allocation,
disbursement and utilization of financial resources. Reporting the
amount that a program has spent or plan to spend might meet this
requirement.
6 Performance targets, outputs and results are defined.a Reporting the performance targets and/or program outputs/outcomes
meets this requirement e.g. number of persons the program plans to
treat. For programs that are already being implemented, reporting both
the performance target and the actual outputs and results is ideal.
7 There is sufficient support for the program amongst political parties,
unions, and civil society organizations.
Government should provide this information.
8 Measures to disclose information to the public, including procurement
information, contractual obligations, evaluation criteria, progress reports,
fund flows, commitments and timelines have been established.
A description of the plan to make program information publicly
available.
Providing program information through webpages, program reports,
annual company reports, etc. might meet this requirement.
Strong risk management and mitigation strategies
1 Risks have been identified. A description of the potential strategic, implementation, and
sustainability risks, harm or unintended consequences might meet this
requirement.
2 Mitigation strategies for each risk, have been developed. A description of how to mitigate any potential strategic,
implementation, and sustainability risks, harm or unintended
consequences might meet this requirement.
3 Due diligence on industry partner has been conducted (including
financial, managerial and implementation capacity assessments).
Company provides information on how it assessed and selected its
partners.
4 Potential conflicts of interest have been identified. A description of any potential conflict of interest meets this requirement
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was limited information on the financial resources bud-
geted or used for the project (n = 7/20; 35%) and the
process for monitoring and evaluation – data collection,
processing, and validation (n = 4/20; 20%).
For the risk management and mitigation strategies do-
main, only one program (a licensing agreement pro-
gram) identified the risks and has risk mitigation
strategies and one program reported on how their part-
ners were selected (a HIV screening and linkage to care
program). None of the programs reported identifying
potential conflicts of interest.
For the transitioning plan for long-term sustainability
domain, more than half of the programs reported on a
strategy or designed their programs in such a way as to
ensure sustainability of health gains (55%) while 35% of
programs were part of existing government program or
will be integrated into the health system. None of the
programs reported developing a clear transition plan for
when the program ends.
Discussion
There is increased demand for greater public accountabil-
ity and transparency of global health partnership pro-
grams. The WHO checklist was developed as a framework
to assess key considerations for evaluating proposals for
access to medicine programs. To our knowledge this is
the first time the checklist has been pilot tested to study
its feasibility as a framework for public reporting of pro-
gram information..
Our study contributes to existing knowledge in several
aspects. First, our results demonstrate the usefulness of
the checklist in systematically assessing programs. Most
of checklist questions ask for information that should be
available to those leading or reporting about the pro-
gram. Setting standards in industry-led social program
reporting is relevant to increase transparency and enable
accountability [15]. Although progress has been made in
reporting on environmental social corporate responsibil-
ity aspects, there is a large body of literature on corpor-
ate social responsibility that shows that industry led
programs lack reporting standards [16, 17]. However,
there are very few publications discussing the expecta-
tions for pharmaceutical-industry led access programs
and their compliance with reporting standards compar-
able to other industries [18].
Second, the piloting of the checklist showed the exist-
ing gaps in the public reporting of program information
and the areas on which companies might need to focus
more attention. We used publicly available program data
because from our perspective, program information that
Table 1 Description of program information that would fulfil the requirements of the corresponding checklist question (Continued)
WHO checklist Description of program information from companies that align with the
checklist
such as potential conflicts between business interests and social
interests (program goals).
Clear transitioning plans for long-term sustainability
1 The program is or will be integrated into the health system. A description of how the program will be integrated into the health
system meets this requirement e.g. incorporating the program’s training
curriculum for midwives into the national training curriculum. A
program that is supporting an existing government program might
meet this requirement.
2 A clear transition plan for when the program ends has been developed. A description of how the program will transition to the local
community/government or made self-sustaining when the funding has
ended meets this requirement. For example, having training participants
pay a training fee to sustain the program.
3 A strategy to ensure sustainability of health gains has been developed. A description of how the program will ensure sustainability of the
health gains meets this requirement e.g. training local health providers
to train other providers who will continue to provide care after the
program has ended.
A program that ensures local ownership of the program might meet
this requirement.
A pricing scheme where patients pay part of the cost of the medicine
might meet this requirement.
A licensing agreement that leads to lower prices for patients might
meet this requirement.
aDouble- or multi-barreled questions (questions that had two or more concepts in a single question)
b We combined two questions: “The initiative can be implemented under existing legislation and it adheres to national regulations, procurement procedures,
treatment guidelines, and standards of care, quality and safety requirements, remuneration scales and hiring practices” and “The program is suitable for the
existing infrastructure, capacity, environment and local context” into one question because of their similarity. Only if both statements applied, we checked
this item
Note: “The policy objective is clear”: for the purposes of this study, we considered program that provided information on their program objectives as having
answered the question
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companies submit to government should be in the pub-
lic sphere to ensure accountability and transparency. In
general, most programs were clear on the public health
needs of their programs, program objectives and activ-
ities and the actual or expected program outputs. How-
ever, there was little information on additional resources
required from or contributed by government and other
stakeholders; program needs assessment, program align-
ment with country plans and capacity, detailed program
monitoring and evaluation plan, risks mitigation strat-
egies and sustainability plans. This finding agrees with
an earlier observation of public-private partnerships by
Buse et al. [7] Specifically, we noted that most programs
did not report their risk management and mitigation
strategies. Though the reason for this finding is not
clear, it could be that the companies did not realize the
importance of such reporting or did not conduct
systematic program risk assessment and so do not have
any information to provide. Assessing potential program
initiation, implementation and sustainability risk, includ-
ing financial sustainability risk is important, as the role
of sustainable funding in program sustainability cannot
be overemphasized [19, 20]. In addition, it is important
to assess the capacity of the implementing partners to
implement the programs as studies have linked program
sustainability to the organizational capacity of the imple-
menting organization [19, 21].
Moreover, companies are currently reporting their pro-
gram objectives and the public health needs that their pro-
grams meet. However, there is paucity of reporting
program needs assessments, as many of the programs were
silent on how or whether the needs assessment influenced
program design. Conducting a needs assessment before the
start of a program is invaluable as it helps organizations to
Table 2 Number of programs that provide information on each checklist question
WHO checklist Total Percent (N =
20)
Alignment with countries’ national health and development plans, needs, capacity, laws and policies 7.86 39.29%
The program serves a public health need. 20 100%
The policy objective is clear. 20 100%
The program aligns with health strategic plans and the general development agenda. 10 50%
The program is suitable for the existing infrastructure, capacity, environment and local context. 4 20%
Additional government resources (infrastructure, human resources or funding) that are required have been identified and are
available.
0 0%
The program does not divert resources away from other public health priorities. 0 0%
The program has been compared to other approaches/programs/ programmes and has been found to be the most suitable. 1 5%
Strong mechanisms to ensure financial, performance, and public accountability 10.75 53.75%
Roles and responsibilities for all stakeholders involved are clear. 7 35%
The mechanisms for how the program will be carried out are clear. 19 95%
Those responsible for overseeing and monitoring the program have been identified. 10 50%
The process for monitoring and evaluation has been established. 4 20%
Allocation, disbursement and utilization of financial resources have been defined. 7 35%
Performance targets, outputs and results are defined. 19 95%
There is sufficient support for the program amongst political parties, unions, and civil society organizations. 0 0%
Measures to disclose information to the public, including procurement information, contractual obligations, evaluation criteria,
progress reports, fund flows, commitments and timelines have been established.
20 100%
Strong risk management and mitigation strategies 0.75 3.75%
Risks have been identified. 1 5%
Mitigation strategies for each risk, have been developed. 1 5%
Due diligence on industry partner has been conducted (including financial, managerial and implementation capacity
assessments).
1 5%
Potential conflicts of interest have been identified. 0 0%
Clear transitioning plans for long-term sustainability 6 30%
The program is or will be integrated into the health system. 7 35%
A clear transition plan for when the program ends has been developed. 0 0%
A strategy to ensure sustainability of health gains has been developed. 11 55%
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use their limited resources to help communities in the most
efficient ways [22]. It is not just important for companies to
do a needs’ assessment; it is also important that the public
are made aware of the evidence and assumptions used to
inform program planning as this will help build public trust
in the program [10]. In addition, all the programs were si-
lent on any additional government resources needed for
their programs. There are concerns that cost of programs
to recipient countries such as the cost of providing a distri-
bution network for donated medicines and training health
workers, might lead to diverting domestic resources from
national priorities, which might worsen the inequalities af-
fecting vulnerable groups [23–25]. To ensure transparency,
it is important that programs report the additional re-
sources required from government or any of its stake-
holders. This will ensure that the contributions of all
stakeholders are fully acknowledged.
Furthermore, apart from one donation program, all the
programs clearly reported on how they are implementing
their programs. The reason for the lack of information on
the donation program, which is part of a Ministry of Health
Pharmaceutical Assistance Program, is not clear. In
addition, all programs, except for one new program that is
still in the need’s assessment stage, reported their perform-
ance target or program output. However, it appears pro-
grams are behind in setting up systems for program
evaluation, as there is paucity of information on the process
for program monitoring and evaluation. This might not be
limited to programs in this study, as earlier studies of access
to medicine programs have shown few independent and
rigorous evaluations of program impact [1].
The transitioning plans for long-term sustainability do-
main has three questions, which appears to follow
Shediac-Rizkallah and Bone three indicators of sustain-
ability [26]. It measured sustainability at: [1] the individual
level - a strategy to ensure sustainability of health gains
[2]; the organization level - a clear transition plan for
when the program ends; and [3] the community level -
the program is or will be integrated into the health system.
While none of the programs reported a clear transition
plan for when the program ends, about a third of the pro-
grams were part of existing government programs or will
be integrated into the health system. An encouraging find-
ing was that more than 50% of programs designed their
programs in ways that will ensure sustainable health gains
for individuals such as training local providers to train
other providers who will continue to provide care after
the program has ended. Overall, though the WHO check-
list was initially prepared for governments to evaluate pro-
posals for access to medicine programs from medicines
and medical device companies, it could also be a frame-
work for the public reporting of program information by
companies. The checklist is setting standards for reporting
that enable governments, civil society, professional
organizations and other advocacy groups to refer to them
and ensure that the information is provided before per-
mission of program operation is granted.
There are some areas in which the WHO checklist
could be strengthened. We noted that the WHO checklist
does not ask any question on how programs address social
inequity. Information on how public-private partnerships
have affected health equity is scarce and programs ability
to address social inequity should be an important consid-
eration in access programs [6]. Social inequities exist be-
tween and within countries with those in disadvantaged
groups having worse health outcomes [27]. The 2015
United Nations sustainable development goals highlights
the importance of reducing inequality within countries as
a key step to ensuring sustainable development [28].
Reporting how access programs plan to address inequity
will make it easier to assess what equity targets are set and
who should be held accountable for achieving those tar-
gets, if any. In addition, the checklist does not ask whether
the program has been evaluated in terms of its perform-
ance. Information on program performance in other set-
tings could provide governments and other stakeholders
with valuable insights about the expected effects of the
program in their country. Whether an impact evaluation
(the extent to which the program’s achievements can be
attributed to the program interventions) or a process
evaluation (the extent to which the program has been im-
plemented as planned) is appropriate depends on a num-
ber of factors. An impact evaluation may be justified for
programs that are expected to be implemented in many
countries and cover a substantial number of people such
as the Novartis Access program which was initially
planned to be implemented in 30 countries [29]. Smaller
programs covering fewer people or programs using inter-
ventions that are well evaluated may not require an impact
evaluation depending on the setting in which they are im-
plemented. Adding the requirement to report on any
process and impact evaluation would enhance the value of
the checklist.
Finally, double or multi-barreled questions can make
respondents uncertain on how to respond to such ques-
tions [30, 31]. One way to deal with those questions will
be to split them into separate questions. For example,
the question “The program aligns with health strategic
plans and the general development agenda” could be
two separate questions, [1] “The program aligns with
health strategic plans” and [2] “The program aligns with
the general development agenda”. Alternatively, the
questions could be modified to make them clearer.
Limitations
There are some limitations to the findings of this study.
First, most of the programs in this study are in low- and
middle-income countries and the findings in this study
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might not be applicable to programs in high-income
countries. Secondly, large research-based pharmaceutical
companies implemented the programs in this study and
the findings might not be applicable to programs imple-
mented by smaller pharmaceutical companies. Further-
more, we could only assess publicly available program
information and could not assess whether companies had
other program information requested in the WHO check-
list that were not publicly available. Currently, most com-
panies instead of independent third parties are providing
data on their access programs. Third party verification of
such program information could enhance its veracity but
is currently not practiced in financial reporting as well as
in many other private sector reporting activities.
Conclusion
The WHO checklist provides a useful tool for assessing
pharmaceutical industry led programs as most of checklist
questions ask for information that should be available to
those leading the program. Further revisions of the WHO
checklist will help in refining it to improve clarity and
content validity. The pilot testing of the checklist showed
the existing gaps in the public reporting of program infor-
mation such as paucity of information on additional re-
sources required from or contributed by government and
other stakeholders, program needs assessment, program
alignment with country plans and capacity, detailed pro-
gram monitoring and evaluation plan, risks mitigation
strategies and sustainability plans.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40545-020-0204-z.
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